|
Age (yrs)
|
61.6 ± 10.0
|
|
Woman (n,%)
|
15 (56)
|
|
Median disease duration (yrs, p25-p75)
|
11.2 (4.2- 17.4)
|
|
Median number of previous DMARDs (n)
|
2.5 (2.0- 3.3)
|
|
Previously treated with another biological (n, %)
|
3 (11%)
|
|
Rheumatoid factor positive (n,%)
|
21 (78)
|
|
Duration of infliximab therapy (yrs)
|
3.7 ± 2.3
|
|
Interval infliximab infusions (wks)
|
6.8 ± 2.0
|
|
Disease Activity at baseline
| |
|
Remission (n,%)
|
7 (26)
|
|
Low disease activity (n,%)
|
6 (22)
|
|
Moderate disease activity (n,%)
|
11 (41)
|
|
High disease activity (n,%)
|
3 (11)
|
|
DMARD at baseline (n,%)
|
23 (85)
|
|
Methotrexate (n,%)
|
17 (63)
|
|
Dose (mg/week)
|
16.8 ± 5.5
|
|
Azathioprine (n,%)
|
4 (15%)
|
|
Prednisone at baseline (n, %)
|
5 (19%)
|
|
Dose (mg/day)
|
5.8 ± 1.8
|
